Dublin, Ireland, November 6, 2012
Inflection Biosciences to attend the the 24th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 6-9, 2012 in Dublin, Ireland.
Hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute, and the American Association for Cancer Research, the 2012 Symposium on Molecular Targets and Cancer Therapeutics will bring together more than 2,000 academics, scientists and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection and the impact of new discoveries in molecular biology.
About Inflection Biosciences Inflection Biosciences is an early stage, drug development company with a focus on developing innovative small molecule therapeutics that address unmet needs for cancer. Inflection Biosciences is dedicated to identifying excellent early stage cancer research from academic institutes and other companies around the world. The company will use its expertise to progress the most promising programs through pre-clinical and early clinical stages, partnering for later stage clinical development and commercialisation. For more information please visit www.inflectionbio.com
Contact: Darren Cunningham, Chief Executive Officer Tel: +353 (0)1 4003615 Email: email@example.com